Use this space to put some text. Update this text in HTML Powered by Blogger.
There was an error in this gadget

Monday, 24 November 2014

Sensex, Nifty at fresh closing high; Infosys hits new high

03:30 pm Market closing: Buoyed by strong global cues both from China and ECB, the market made record highs and finally ended at a new closing high. The Sensex was up 164.91 points at 28499.54 and the Nifty was up 52.80 points at 8530.15. About 1346 shares advanced, 1734 shares declined and 116 shares are unchanged.

Metals gained the most with Tata Steel and Hindalo as lead gainers. ICICI Bank, Infosys contributed over 60 percent to the Nifty gain. Infosys, ICICI Bank, HDFC Bank, Lupin and Bajaj Auto hit record highs while oil stocks were laggards throughout the day.

3:00 pm Fresh funds? SpiceJet is in "exploratory and preliminary stage" talks with investors about raising fresh capital, the budget airline said in a regulatory statement.

The airline said a few parties had approached it about making an investment but because the talks were at an early stage it would be improper to comment on the specifics of any possible stake sale.

SpiceJet, which has lost money for five consecutive quarters, has been trying to raise new money for much of this year. The airline said in May it was in "advanced" talks for a capital infusion but no deal materialised.

2:30 pm Launch: Dr Reddy's Laboratories has launched Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a generic version of Taxotere (docetaxel injection) in the US market.

Dr Reddy's Abbreviated New Drug Application (ANDA) is approved by the United States Food & Drug Administration (USFDA), DRL said in a statement today. Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Its brand and generic versions have US sales of approximately USD 218 million MAT for the most recent 12 months ending in September, the drug maker said quoting IMS Health data. More information please visit this site

No comments:

Post a Comment